CSANZ 2022

Sponsored Symposia


07.45 - 08.30am, Friday 11 December

XIENCE 90/28: Assessment of three-month and one-month DAPT after everolimus-eluting stents in high-bleeding risk patients

Speaker: Prof. Marco Valgimigli, Bern, Switzerland
Moderator: Dr Krishna Sudhir, Divisional Vice President Medical Affairs, Abbott
Live Q&A and Panel: Ravi Bhindi, North Shore Private Hospital, Dr Sidney Lo, Liverpool Hospital. Dr Jithendra Somaratne, Auckland City Hospital

Innovations in transcatheter technologies  

Moderator: Simon Williamson, Business Unit Director, TMTT, Edwards Lifesciences
Speakers: Associate Professor Martin Ng, Royal Prince Alfred Hospital and Dr Ted Feldman, VP Medical Affairs, Edwards Lifesciences

Introducing the Edwards Innovations in Transcatheter Technology ANZET Breakfast Session. An opportunity to review the Edwards History of Innovation and Commitment to portfolio developments in Tricuspid and Mitral Technology with Dr Ted Feldman, and an insightful review of the PASCAL system and recent clinical experience with A/Prof Martin Ng. We look forward to meeting with you.

Low Risk - Perspectives in clinical practice and their impact 

Speakers: A/Prof Tony Walton, VIC; Dr Michael Reardon, USA; Prof David Muller, NSW

With private reimbursement on the horizon for Intermediate and Low Risk here in Australia, this webinar delves into the key data, insights surrounding indication change. We get a US perspective from Cardiothoracic Surgeon Dr. Michael Reardon, and also local insights on the new TGA approvals and the path to reimbursement from Prof. David Muller. Finally, we end with a round-table covering all facets including patient viability, hemodynamics and patient selection with A/Prof. Tony Walton. Join us for what should be a fascinating look at this changing landscape. 

A paradigm shift in the treatment of atrial fibrillation? The case for early Cyroablation

Speaker: Dr Stewart Healy, VIC

Three clinical trials (CryoFirst, STOP AF First & EARLY AF) have been presented and two published in 2020 that have compared Cryoablation to Antiarrhythmic Drugs (AADs) in a symptomatic, Drug Naïve, Paroxysmal Atrial Fibrillation patient population. Dr Stewart Healy, a Cardiac Electrophysiologist from Monash Medical Centre, Victoria was an investigator in the CryoFirst trial and will be presenting an overview of these three recent trials. Current guidelines recommend the use of AADs as the preferred first line approach to treat patients with Paroxysmal Atrial Fibrillation, however these three recent clinical trials now show statistically significant, higher rates of freedom from AF at 12 months for patients treated with Cryoablation when compared to the patients treated with AAD therapy. Research showing that Atrial Fibrillation is a progressive disease and the implications that these trials could have on clinical practice into the future will also be discussed. 

Affirm-AHF Highlights - Ferinject®'s potential to improve heart failure (HF) management1

Speaker: Professor Andrew Sindone

Iron deficiency is an important co-morbidity in HF affecting approximately 50% of patients. Previous studies with IV ferric carboxymaltose has shown improvements in symptoms, exercise capacity, functional capacity and quality of life in HF patients with reduced ejection fraction. A meta-analysis has shown reduction in HF hospitalizations with IV ferric carboxymaltose. Hospitalisation for acute heart failure (AHF) is frequent in HF patients over 65 years of age, and it’s associated with an increased risk of death. AFFIRM-AHF was recently presented at the American Heart Association meeting and is the first international, double-blind, randomised controlled trial to compare the effect of IV ferric carboxymaltose versus placebo on cardiovascular (CV) mortality and HF hospitalisations in patients with stabilised acute HF and iron deficiency.

References: Ponikowski P, et al. Lancet. November 13 2020. e-pub ahead of print: doi.org/10.1016/S0140-6736(20)32339-4